Semax for Sale: The Fields HPLC and LAL Can Settle

Every Semax for sale page is a list of assertions, and the useful skill is telling apart the ones an assay result could contradict from the ones that are only shaped like information. Roughly half of a typical listing falls into the second group.

The test applied throughout is deliberately narrow. A field earns its place if a named assay, a document or the parcel itself could later contradict it. Everything that cannot be contradicted, however confidently it is written, is decoration, and decoration is what a listing designed to look legitimate consists almost entirely of.

Semax for sale: the fields an assay can contradict, and which assay

The right-hand column is the whole exercise. If no assay, document or physical object can be named there, the field is not evidence regardless of how specific it sounds.

Two rows deserve flagging before the table rather than after it. Grade language is listed because it is the field readers most often treat as a specification: research grade, pharmaceutical grade and laboratory grade have no agreed definitions for a substance with no monograph, so they describe an intention rather than a standard. Storage condition is listed because it is the only field on the list that the parcel itself can falsify without any document at all.

The quantity line, and the number the listing does not use

Listings sell a 10 mg vial. The batch report for 30-05260628 records a labelled quantity of 10 mg and a measured net content of 11.23 mg, an overfill of about 12 percent. Overfill is ordinary in lyophilised presentations and it is not a discount, but it does mean the two numbers in the transaction are not the same number, and only one of them was weighed.

The consequence is arithmetic rather than moral. Any per-milligram figure computed from the label is nominal by construction, including the $3.00 per milligram that follows from $30.00 for a nominal 10 mg. A listing that quotes the measured content alongside the label is telling you more than one that quotes only the label, and a listing that quotes only a purity percentage is telling you the least of the three. The same collision between a declared mass and an assayed one, on the neighbouring product from the same vendor, is worked through in our page on how a quantity result can contradict a listing.

The testing scope line, which separates two listings that read alike

Two product pages can carry the same purity claim and rest on entirely different amounts of work, and the scope line is where that becomes visible. The Semax certificate here runs to four pages under report number KVR-2026-E848E0, issued by Kovera Labs and certified 15 June 2026. Page one gives purity of 99.886 percent against a specification of not less than 98 percent, net content, identity by LC-MS, an endotoxin screen and a sterility screen, with the chromatographic conditions stated as reversed-phase HPLC on a C18 column with diode array detection at 214 nm. Page two is a bacterial endotoxin report: a kinetic LAL assay run on 29 May 2026 to USP Chapter 85, against an E. coli O111:B4 reference standard, over a declared detection range of 0.01 to 1.0 EU/mL, in an LAL reagent water matrix, returning under 0.20 EU/mL against a 0.5 EU/mL acceptance limit across a 2.0 mL dilution volume, which is under 0.40 EU in total for the vial, with positive and negative controls both behaving as expected. Page three is elemental impurities by ICP-MS with spike recoveries of 98, 102, 95 and 91 percent inside a 70 to 150 percent criterion. Page four is a rapid sterility screen reporting no growth for aerobic and anaerobic bacteria and no fungi or yeast after two days at 30 to 35 degrees Celsius.

Two details on those pages are worth a reader’s attention because they are the sort of thing a listing will never surface. The sterility page states in its own text that what was performed is a rapid screening method and that full USP Chapter 71 sterility testing may be required for regulatory compliance, which is the document declining to overclaim on its own behalf. And the endotoxin page reports sample coefficient of variation, spike coefficient of variation and spike recovery all as not applicable, so the test for interfering factors that would show the sample matrix is not suppressing the assay does not appear on the page. Neither observation undoes the result. Both are things you can only learn by opening the document rather than trusting the listing that links to it.

The fields a fabricated listing leaves out, and one it cannot fake easily

Absences cluster in a recognisable pattern. A listing built to look legitimate rather than to be checkable will carry a purity percentage, a molecular formula copied from a database, a stock image and a paragraph of reassurance, and will omit the lot number, the laboratory name, the testing scope and the analysis date. Every omitted item is one that could be contradicted later, which is not a coincidence.

The copied formula is worth a second look, because it is the field that most often gives a thin listing its air of precision. C37H51N9O10S is correct: it is what PubChem records for CID 9811102, with a molecular weight of 813.9, for the seven-residue sequence Met-Glu-His-Phe-Pro-Gly-Pro, which is the ACTH(4-7) fragment carrying a Pro-Gly-Pro tail. Being correct is exactly why it proves nothing. A formula is a property of the compound and can be copied in a second by anyone selling anything, so it tells you what the seller intended to sell rather than what is in the vial. The number that would connect the two is a measured mass on an identity page, and on this certificate that number is not printed.

One field on this particular certificate is unusually hard to imitate and unusually easy to check: the vial description. The report states a red cap and a silver crimp alongside the batch number, which are physical attributes of the container that either match what arrives or do not. Add the printed verification address at koveralabs.com and a per-report access code on each page, and the document at least contemplates being checked against the issuing laboratory rather than against the seller. Whether a code returns anything is worth testing rather than assuming, and the wider question of which declarations on a vial listing carry weight is set out in our guide to what a lyophilised vial must declare.

What no Semax listing is entitled to claim

Three claims recur and none of them survives contact with the record. The first is approval: there is none, for any indication, anywhere in the United States. The second is regulatory standing of some vaguer sort, usually a reference to category 2, which is stale rather than merely wrong. Semax was nominated for the 503A bulks list, was placed in category 2 under the interim policies while FDA evaluated it, and the nomination was then withdrawn by the nominator. It appears today on FDA’s safety risks page under the heading for substances previously in category 2 that were withdrawn, and current category 2 holds six substances of which Semax is not one.

The third is efficacy, and it is the one a good certificate makes most tempting. FDA states that compounded drugs containing semax may pose a risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities, that it has no or limited safety-related information for proposed routes of administration, and that it therefore lacks sufficient information to know whether the drug would cause harm if administered to humans. Endotoxin and impurity testing speaks to the first clause. Nothing speaks to the last one, and a search of ClinicalTrials.gov returns no registered study with Semax as an intervention. Which listing statements can be tested at all is a question we work through for a different compound in our page on which listing claims are testable.

A four-line check for any listing you find

1. Find the lot number on the page. If there is not one, stop; nothing further can be verified.
2. Open the certificate and confirm the same lot number appears in its header, and that the client named on it is the seller you are buying from.
3. Count the tests. Purity alone, purity plus identity, or purity plus identity plus microbiology are three different products from a documentary point of view.
4. Check the analysis date against the age of the listing. A report from months ago describes the batch it names and nothing that was filled since.

Four lines is enough to sort most of this market, and a listing that fails at line one is not a cheaper version of a listing that passes at line four. It is a different kind of offer, one that has arranged itself so that nothing it says can be shown to be untrue.